RNA Analytical/Quality Videos

  1. LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma 2/17/2025

    This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

  2. Real-Time Monitoring Of Higher-Order Structure Of RNAs 9/10/2025

    Learn how a new biophysical characterization strategy can enhance RNA therapeutic candidate screening and formulation development through a deeper understanding of RNA structure under native conditions.

  3. Bridging the Gap Between Analytical Control & Translation 6/9/2026

    Though we may have increasingly clear understandings of our mRNA-LNP products structurally, understanding our products’ cellular function remains challenging without extensive clinical data. Here, this Advancing RNA panel featuring AbbVie’s Elaine Peters, Tessera’s Ilya Shestopalov, and Sanofi’s Philippe Talaga addresses what innovation — both in research and method development — can help us get more functional information about our molecules as we wait for more clinical development.  

  4. What's In The Vial?! A [Brief] Meditation On Control Strategy

    Speakers in The State Of The mRNA Supply Chain event tackle an audience member’s question around what matters most: What’s in the vial or what’s in the process?

  5. Outgrowing Legacy Methods: mRNA's Transition from Protein Paradigms 6/9/2026

    AbbVie’s Elaine Peters, Sanofi’s Philippe Talaga, and Tessera’s Ilya Shestopalov highlight the technical limitations of legacy analytical methods in evaluating and measuring mRNA-LNP concentration, structure, purity, integrity, and impurities.

  6. How Is mRNA "Shaking Up" Our Regulatory Interactions & Operations Today? 5/10/2024

    The Advancing RNA Live panelists share several inconsistencies they’ve encountered working with global regulators, as well as on which aspects they’re seeing regulatory agencies applying greater scrutiny in mRNA development today.

  7. Decoding Regulatory Expectations: The Art Of A Successful IND Submission 6/24/2025

    Companies often underestimate the information required for IND submissions, particularly in a sector that’s as diverse as the mRNA sector. Here, former FDA reviewer Tiffany Lucas shares some of the missteps companies can make when first approaching the FDA with their IND. CureVac’s Ulrike Jägle furthers the discussion, offering a critical best practice she and her colleagues rely upon as well to streamline their regulatory interactions.

  8. Real-Time Protein Titer Measurements: Simple, Automated, And Compact Solution 7/3/2025

    Accelerate your workflow with an automated IgG titer solution. Obtain precise results quickly, enhancing efficiency from process development to manufacturing.

  9. Which mRNA-LNP Attributes Deserve Deeper Characterization Today? 6/9/2026

    This Advancing RNA Live panel comprising Elaine Peters, Ilya Shestopalov, and Philippe Talaga addresses which mRNA-LNP attributes could benefit the most from orthogonal extended characterization.   

  10. Is QbD Actually Possible In mRNA Development Today? 8/22/2024

    As the panelists of this Advancing RNA LIVE discussion argue, there are several big limitations we face in implementing QBD today for RNA development.